MARKET

ITCI

ITCI

INTRA CELLULAR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.21
-1.18
-4.29%
After Hours: 26.25 +0.05 +0.17% 19:18 09/24 EDT
OPEN
27.15
PREV CLOSE
27.38
HIGH
27.15
LOW
25.67
VOLUME
1.46M
TURNOVER
--
52 WEEK HIGH
43.56
52 WEEK LOW
6.75
MARKET CAP
2.06B
P/E (TTM)
-8.5834
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Insider Weekends: Tamara Gustavson Puts $8 Million Into Public Storage
Insider buying increased significantly last week.Notable Insider Buys: Public Storage, IGM Biosciences, Inc., Cassava Sciences, Inc., Intra-Cellular Therapies, Inc., Nikola Corporation.Notable Insider Sells: Scientific Games Corporation, Guardant Health, Inc., Antero Midstream Corporation, The Boston Beer Company, Inc., Zscaler, Inc.
Seekingalpha · 3d ago
Intra-Cellular Therapies (ITCI) Investor Presentation - Slideshow
The following slide deck was published by Intra-Cellular Therapies, Inc. in conjunction with this event.
Seekingalpha · 09/17 23:20
Intra-Cellular Therapies to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
NEW YORK, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman
GlobeNewswire · 09/15 12:00
Intra-Cellular Therapies to Present at the Cantor Virtual Global Healthcare Conference
NEW YORK, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman
GlobeNewswire · 09/14 13:00
What Kind Of Investors Own Most Of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)?
A look at the shareholders of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) can tell us which group is most powerful...
Simply Wall St. · 09/11 13:42
ITCI, AMRS among premarket losers
Evofem Biosciences (EVFM) -14%.Amyris (AMRS) -11% after Lavvan files $881M lawsuit.Muscle Maker (GRIL) -11%.Brigham Minerals (MNRL) -10% after pricing secondary offering.Satsuma Pharmaceuticals (STSA) -7% on yesterday's news of late-stage STS101 study and analysts downgrade.Spero Therapeutics (SPRO) -8% after pricing equity
Seekingalpha · 09/11 12:21
Stick With the Intra-Cellular Rally for Another 25% Upside, Says Analyst
TipRanks · 09/10 17:38
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Sarepta Flags Potential Delay In Gene Therapy Trial
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9)
Benzinga · 09/10 11:20
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ITCI. Analyze the recent business situations of INTRA CELLULAR through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ITCI stock price target is 54.33 with a high estimate of 80.00 and a low estimate of 35.00.
EPS
Institutional Holdings
Institutions: 222
Institutional Holdings: 52.65M
% Owned: 67.11%
Shares Outstanding: 78.44M
TypeInstitutionsShares
Increased
58
4.85M
New
55
-1.57M
Decreased
32
2.32M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chief Financial Officer/Senior Vice President - Finance/Treasurer/Assistant Secretary
Lawrence Hineline
Executive Vice President/General Counsel/Secretary
Michael Halstead
Executive Vice President
Mark Neumann
Executive Vice President
Andrew Satlin
Senior Vice President/Chief Scientific Officer
Robert Davis
Senior Vice President
John Bardi
Senior Vice President
Suresh Durgam
Senior Vice President
Michael Olchaskey
Senior Vice President
Kimberly Vanover
Lead Director/Independent Director
Robert Van Nostrand
Director/Chief Executive Officer/President/Chairman
Sharon Mates
Independent Director
Christopher Alafi
Independent Director
Richard Lerner
Independent Director
Joel Marcus
Independent Director
Rory Riggs
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ITCI
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Intra-Cellular Therapies Inc stock information, including NASDAQ:ITCI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ITCI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ITCI stock methods without spending real money on the virtual paper trading platform.